Early cholesterol-lowering drug after heart attack study
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether starting evolocumab (a cholesterol-lowering injection) soon after a heart attack helps prevent future heart problems. You'll receive the study drug or placebo for 52 weeks while your heart is monitored with imaging scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Had a heart attack (STEMI, NSTEMI, or unstable angina) treated with stent placement in the last week
- Age 40–75 years
- High cholesterol (LDL-C) that isn't well controlled by statins alone
- Willing to have heart imaging scans and blood tests at the start and follow-up visits
- Able to commit to 52 weeks of follow-up care and study visits
- No previous heart surgery, bypass, or prior stent placements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a single injection of a PCSK9 inhibitor (a cholesterol-lowering medicine) can improve heart health after a stent procedure. It is for people who have a certain amount of fat buildup in their treated artery.
This trial tests whether a powerful cholesterol-lowering drug (PCSK9 inhibitor) helps stabilize plaque in heart arteries after a recent heart attack or unstable angina treated with a stent. It may lower the risk of future heart problems.
This trial studies whether lowering LDL (“bad cholesterol”) with a PCSK-9 inhibitor (evolocumab) improves blood flow to the heart, measured by special PET scans. It’s for people over a certain age who have stable coronary artery disease and a higher risk of heart problems.
This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.
This study tests whether a stronger-than-usual cholesterol-lowering treatment right after a heart attack (STEMI or NSTEMI) can improve outcomes. It may help protect the heart by lowering harmful cholesterol quickly.
This trial tests giving strong cholesterol-lowering medicine within 24 hours after a heart attack to see if it helps recovery. It is for people who have had a recent heart attack and are getting a stent placed.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.